Ambrx Granted Orphan Drug Designation for ARX788 for the Treatment of Gastric Cancer
Ambrx was granted orphan drug designation by the FDA for its drug ARX788, which is in clinical trials to treat HER2-positive gastric... Read More
Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma
Adding Herceptin to chemotherapy improved outcomes for patients with HER2-positive advanced gastric cancer in a clinical trial.
Enhertu granted Priority Review in the US for the treatment of HER2-positive metastatic gastric cancer
AstraZeneca and Daiichi Sankyo were granted priority review by the FDA for Enhertu to treat HER2-positive gastric or gastroesophageal junction cancer, with... Read More
Enhertu now approved in Japan for gastric cancer
Enhertu from Daiichi-Sankyo is now approved in Japan for the treatment of HER2-positive gastric cancer.
Pieris and Lilly enter into a Clinical Trial Collaboration to Evaluate Combination of PRS-343 with Ramucirumab and Paclitaxel in Gastric Cancer
Pieris and Eli Lilly have partnered to test a combination of Cyramza, paclitaxel and Pieris’ novel bispecific antibody in HER2-positive gastric cancer.
Biosimilar Trastuzumab Effective in Triplet Regimen for Gastric Cancer
A biosimilar version of Herceptin taken in combination with chemo and the immune-boosting drug Keytruda reduced tumor size in a clinical trial... Read More
Drug-Drug Interactions to Avoid in Patients With GI Cancer
People with HER2-positive gastric cancer should not take proton pump inhibitors for heartburn while they are undergoing treatment, recent studies have found.
RemeGen Co., Ltd. Announced New RC48-ADC Data in Patients with Advanced Gastric Cancer at ASCO
RemeGen announced a 24% response rate in a clinical trial of its antibody drug conjugate RC48 in patients with HER-2 positive gastric... Read More
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
Gastric cancer patients treated with Enhertu in a recent study had favorable response rates, survival and duration of response as compared to... Read More
First-Line Pembrolizumab and Trastuzumab in HER2-Positive Esophageal, Gastric, or Gastroesophageal Junction Cancer
Patients with Her2-positive gastric cancer taking a combination of the immune-boosting drug Keytruda with Herceptin had progression-free survival rate at six months... Read More